Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biohaven Ltd. (BHVN) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Biohaven Ltd. (NYSE:BHVN) Shares Purchased by Principal Financial Group Inc.
Principal Financial Group Inc. raised its holdings in Biohaven Ltd. (NYSE:BHVN – Free Report) by 4.4% in the 4th quarter, ...
Biohaven (NYSE:BHVN) Trading Down 6.1% After Earnings Miss
Biohaven Ltd. (NYSE:BHVN – Get Free Report) fell 6.1% during mid-day trading on Monday after the company announced weaker ...
Estimating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$28.35 With US$31.37 ...
Nasdaq2d
Biohaven Ltd. Q4 Loss Increases, Misses Estimates
(RTTNews) - Biohaven Ltd. (BHVN) released Loss for its fourth quarter that increased from last year and missed the Street estimates. The company's bottom line totaled -$186.84 million, or -$1.85 ...
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained ...
Yahoo Finance23d
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...
Morningstar2d
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...
Biohaven Ltd.: Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...
The Victoria Advocate23d
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
NEW HAVEN, Conn., Feb. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the US Food and Drug Administration (FDA) has accepted for review the ...